業績公告
即時報告
8-K
2026-08-07
Treace Medical Concepts上調全年指引 次季虧損收窄至1590萬美元
AI 繁中摘要
📄 申報類型：8-K（業績公告）
Treace Medical Concepts（納斯達克：TMCI）公佈截至2026年6月30日止第二季度財務業績。
💰 第二季度業績重點
• 收入為4,540萬美元，按年下跌4%，對比2025年同期為4,740萬美元；但按季比較，按年增長率有所改善。
• 毛利率為78.5%，略低於2025年同期的79.7%。
• 淨虧損為1,590萬美元（每股虧損0.24美元），2025年同期淨虧損為1,740萬美元（每股虧損0.28美元），虧損幅度收窄。
• 經調整EBITDA為負350萬美元，2025年同期為負360萬美元。
• 總營運開支下降8%至5,060萬美元，主要受惠於針對性的成本削減措施。
• 今年至今現金使用量較2025年同期減少57%（相當於節省360萬美元）。截至2026年6月30日，現金、現金等價物及有價證券合共4,560萬美元，另設有1.15億美元信貸額度。
🦴 業務及產品進展
• 已啟動SuperBite™壓縮螺釘系統的有限市場發佈。
• 完成HyperPlate™ XM動態加壓鎖定植入系統的首宗手術個案。
• Lapiplasty®外科醫生的新產品組合採用率持續上升，約40%的Lapiplasty®醫生用戶已使用2025年第三季度推出的三個新拇囊炎矯正系統之一，高於2026年第一季度的35%。
📈 2026年全年指引（更新）
• 收入指引上調至2.04億至2.12億美元，按年跌幅介乎4%至0%（此前為2.02億至2.12億美元）。
• 經調整EBITDA虧損指引收窄至300萬至500萬美元（此前為虧損400萬至600萬美元）。
• 管理層重申全年現金使用量將較2025年減少約50%。
• 公司預期下半年按年增長率持續改善，手術量繼續增長。
🧑⚕️ 管理層評論
行政總裁John T. Treace表示，第二季度業績受惠於手術量按年加速增長，以及醫生對產品組合的採用率提升；公司將繼續投資增長項目，同時推動盈利能力，為下半年更強勁增長做好準備。
📊 對投資者的潛在影響
公司第二季度收入雖然錄得按年倒退，但虧損收窄、現金消耗大幅減少，並上調全年收入及盈利指引，反映經營效率改善。新產品推出及醫生採用率提升，有助擴大拇囊炎手術市場覆蓋，惟仍需留意宏觀經濟不明朗及消費者信心疲弱對選擇性手術需求的潛在影響。
展開英文正文
EX-99.1
2
tmci-ex99_1.htm
EX-99.1
EX-99.1
Exhibit 99.1
Treace Medical Concepts Reports Second Quarter 2026 Financial Results
PONTE VEDRA, Fla. – August 7, 2026 – Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related deformities, today reported financial results for the second quarter ended June 30, 2026.
Recent Highlights
•Generated revenue of $45.4 million in the second quarter 2026 compared to $47.4 million in the same period in 2025.
•Reported second quarter 2026 net loss of $(15.9) million and adjusted EBITDA of $(3.5) million in the second quarter 2026.
•Reduced year-to-date cash usage by 57% or $3.6 million when compared to the same period in 2025. Cash, cash equivalents, and marketable securities totaled $45.6 million as of June 30, 2026.
•Initiated limited market release of SuperBite™ Compression Screw System and completed the first surgical case with HyperPlate™ XM Dynamic Compression Locking Implant System.
•Increased adoption of expanded bunion portfolio with approximately 40% of Lapiplasty® surgeon users incorporating one or more of its three new bunion systems launched in the third quarter 2025 from 35% in the first quarter of 2026.
"We are pleased with our second quarter results which were driven by accelerating year-over-year case volumes and market share gains resulting from increasing surgeon adoption of our comprehensive bunion portfolio as well as our expanding line of new technologies - now providing us access to a broader range of procedures throughout the foot & ankle," said John T. Treace, CEO and Chairman of Treace Medical.
"We continue to focus on investing in growth initiatives to leverage our expanded portfolio, while driving profitability, positioning us for stronger growth in the second half of the year."
Second Quarter 2026 Financial Results
Revenue for the second quarter of 2026 was $45.4 million, representing a decrease of 4% compared to $47.4 million in the second quarter of 2025, and a sequential improvement in year-over-year growth rate.
Gross profit for the second quarter of 2026 was $35.6 million compared to $37.8 million in the second quarter of 2025. Gross margin was 78.5% in the second quarter of 2026, compared to 79.7% in the second quarter of 2025.
Total operating expenses decreased 8% to $50.6 million in the second quarter of 2026 and decreased by $4.2 million compared to total operating expenses of $54.7 million in the second quarter of 2025, primarily driven by targeted expense reduction initiatives across the organization.
Second quarter 2026 net loss was $(15.9) million, or $(0.24) per share, compared to $(17.4) million, or $(0.28) per share, for the same period in 2025. Adjusted EBITDA was $(3.5) million in the second quarter of 2026 compared to $(3.6) million for the same period in 2025. The financial tables and description below provide additional information and a reconciliation of non-GAAP financial information.
Page | 1
Year-to-date cash usage was reduced by 57% or $3.6 million when compared to the same period in 2025. Cash, cash equivalents, and marketable securities totaled $45.6 million as of June 30, 2026. The Company’s existing credit facility provides an additional $115 million of liquidity subject to certain conditions.
2026 Financial Outlook
The Company is raising its full-year 2026 revenue guidance to be in the range of $204 million to $212 million, representing a decline of 4% to 0% compared to full-year 2025. This compares to previous revenue guidance of $202 million to $212 million.
The Company is updating its expectation of a loss in Adjusted EBITDA in the range of $3.0 million to $5.0 million for full year 2026, as compared to previous guidance of a loss in the range of $4.0 million to $6.0 million. The Company reported a loss of $3.9 million in the full-year 2025.*
The Company reiterates its expectation for a reduction in cash usage of approximately 50% for full-year 2026 as compared to the full year 2025.
The Company’s full-year 2026 guidance assumes continued case volume growth and improving year-over-year growth rates for the second half of the year as headwinds are annualized.
Webcast and Conference Call Details
Treace will host a conference call today, August 7, 2026, at 8:00 a.m. ET to discuss its second quarter 2026 financial results. Investors interested in listening to the conference call may do so by registering. The live webcast of the conference call will be available on the Investor Relations section of the Company’s website at investors.treace.com. The webcast will be archived on the website following the completion of the call.
Use of Non-GAAP Financial Measures
To supplement the financial results presented in accordance with GAAP, this earnings release presents Adjusted EBITDA, which the Company defines as net loss before depreciation and amortization expense, interest income, interest expense, taxes, share-based compensation expense, acquisition-related costs, restructuring costs, customer credit loss, litigation costs, and debt extinguishment loss. Non-GAAP financial measures such as Adjusted EBITDA are presented in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Management uses non-GAAP financial measures to evaluate the Company’s operating performance and trends, as well as for making planning decisions. The Company believes that Adjusted EBITDA helps to identify underlying trends in the Company’s business that may otherwise be masked by the effect of the income and expenses and other items that it excludes in its calculation of Adjusted EBITDA. Accordingly, the Company believes this non-GAAP financial measure provides useful information to investors and others in understanding and evaluating the Company’s operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by the Company’s management in their financial and operational decision-making. The Company also presents this non-GAAP financial measure because it believes investors, analysts and rating agencies consider it to be a useful metric in measuring the Company’s performance against other companies and its ability to meet its debt service obligations.
There are limitations related to the use of non-GAAP financial measures such as Adjusted EBITDA because they are not prepared in accordance with GAAP, may exclude significant income and expenses required by GAAP to be recognized in the Company’s financial statements, and may not be comparable to non-GAAP financial measures used by other companies. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. A reconciliation between GAAP and non-GAAP results is presented below.
Page | 2
*A reconciliation of Adjusted EBITDA to GAAP net loss on a forward-looking basis is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to the items excluded from this non-GAAP measure.
Forward-Looking Statements
This press release and statements made during the Company’s earnings call contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company’s: 2026 full-year guidance; anticipated liquidity; 2026 Adjusted EBITDA guidance; expected 2026 cash usage decrease; anticipated return to stronger growth in the second half of the year; anticipated continued case volume growth; expected increase in product adoptions, portfolio utilization and market share; continued execution of commercial and other strategic initiatives; ability to effectively respond to and mitigate the impact of challenges in the current market environment, including in response to increased competition, evolving surgeon and patient preferences for minimally invasive bunion solutions, changes in tariffs and trade policies, protracted government shutdowns, and lower patient demand for elective bunion surgery due to macroeconomic uncertainty and soft consumer sentiment; anticipated future product launches and the timing of such product launches; ability to increase procedure volumes, expand surgeon relationships and utilization rate, and increase procedure penetration and market share; ability to protect and enforce its intellectual property rights, including through its patent infringement and unfair competition suits; success in defending against securities class actions and infringement of its intellectual property by third parties, including its competitors; expected seasonality; ability to leverage investments in its commercial organization and control costs in its organizational structure; anticipated expansion of clinical evidence; the amount and timing of orders for our products from stocking distributors and other customers; and anticipated pace of growth in the foot and ankle market. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace’s public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 27, 2026. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise. The Company’s results for the quarter ended June 30, 2026 are not necessarily indicative of its operating results for any future periods.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of being the recognized leader in the surgical treatment of bunions and related deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for
Page | 3
minimally invasive osteotomy procedures, namely the Nanoplasty® 3D Minimally Invasive Bunion Correction System and the Percuplasty® Percutaneous 3D Bunion Correction System, and the SpeedMTP® MTP Fusion System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate® rapid compression implant platform to new applications, providing surgeons with advanced digital solutions with its IntelliGuide® patient specific, pre-op planning and cut guide technology, and offering SuperBite™ fully-threaded compression screws for use in fusions throughout the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical ConceptsMark L. HairChief Financial Officer
[email protected]
(904) 373-5940
Investors:
Gilmartin Group
Philip Trip Taylor
[email protected]
Page | 4
Treace Medical Concepts, Inc.
Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
(unaudited)
Three Months EndedJune 30,
Six Months EndedJune 30,
2026
2025
2026
2025
Revenue
$
45,376
$
47,387
$
92,574
$
99,957
Cost of goods sold
9,769
9,635
19,560
20,312
Gross profit
35,607
37,752
73,014
79,645
Operating expenses
Sales and marketing
30,940
33,084
64,715
69,206
Research and development
4,376
5,498
8,998
11,060
General and administrative
15,249
16,144
31,426
31,935
Total operating expenses
50,565
54,726
105,139
112,201
Loss from operations
(14,958
)
(16,974
)
(32,125
)
(32,556
)
Interest income
445
775
946
1,616
Interest expense
(1,562
)
(1,321
)
(3,132
)
(2,632
)
Other income, net
202
122
477
252
Other non-operating income (expense), net
(915
)
(424
)
(1,709
)
(764
)
Net loss
$
(15,873
)
$
(17,398
)
$
(33,834
)
$
(33,320
)
Other comprehensive income (loss)
Unrealized gain (loss) on marketable securities
(26
)
(7
)
(124
)
(47
)
Comprehensive loss
$
(15,899
)
$
(17,405
)
$
(33,958
)
$
(33,367
)
Net loss per share, basic and diluted
$
(0.24
)
$
(0.28
)
$
(0.52
)
$
(0.53
)
Weighted-average shares used in computing net loss per share, basic and diluted
65,049,844
63,006,891
64,822,526
62,843,337
Page | 5
Treace Medical Concepts, Inc.
Balance Sheets
(in thousands, except share and per share amounts)
(unaudited)
June 30,
December 31,
2026
2025
Assets
Current assets
Cash and cash equivalents
$
12,610
$
10,708
Marketable securities, short-term
33,009
37,659
Accounts receivable, net of allowance for credit losses of $1,597 and $1,824 as of June 30, 2026 and December 31, 2025, respectively
28,732
42,155
Inventories
39,542
36,031
Prepaid expenses and other current assets
6,561
5,501
Total current assets
120,454
132,054
Property and equipment, net
32,496
29,752
Intangible assets, net of accumulated amortization of $2,850 and $2,375 as of June 30, 2026 and December 31, 2025, respectively
6,650
7,125
Goodwill
12,815
12,815
Operating lease right-of-use assets
7,139
7,614
Other non-current assets, net of allowance for credit losses of $35 and $69 as of June 30, 2026 and December 31, 2025, respectively
1,501
1,221
Total assets
$
181,055
$
190,581
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable
$
16,061
$
6,726
Accrued liabilities
6,281
5,784
Accrued commissions
6,740
9,365
Accrued compensation
8,087
6,331
Other liabilities
4,327
2,429
Total current liabilities
41,496
30,635
Long-term debt, net
56,042
55,583
Operating lease liabilities, net of current portion
13,091
13,982
Other long-term liabilities
2,689
3,049
Total liabilities
113,318
103,249
Stockholders’ equity
Preferred stock, $0.001 par value, 5,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 0 shares issued as of June 30, 2026 and December 31, 2025
—
—
Common stock, $0.001 par value, 300,000,000 shares authorized; 65,236,297 and 64,029,378 shares issued as of June 30, 2026 and December 31, 2025, respectively
65
64
Additional paid-in capital
351,966
337,371
Accumulated deficit
(282,826
)
(248,992
)
Accumulated other comprehensive income (loss)
(52
)
72
Treasury stock, at cost; 259,673 and 165,513 shares as of June 30, 2026 and December 31, 2025, respectively
(1,416
)
(1,183
)
Total stockholders’ equity
67,737
87,332
Total liabilities and stockholders’ equity
$
181,055
$
190,581
Page | 6
Treace Medical Concepts, Inc.
Statements of Cash Flows
(in thousands)
(unaudited)
Six Months Ended June 30,
2026
2025
Cash flows from operating activities
Net loss
$
(33,834
)
$
(33,320
)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Depreciation and amortization expense
2,787
5,037
Provision for allowance for credit losses
243
581
Share-based compensation expense
14,497
18,270
Non-cash lease expense
1,103
1,133
Amortization of debt issuance costs
505
148
Amortization (accretion) of premium (discount) on marketable securities, net
11
(114
)
Other, net
1,383
219
Net changes in operating assets and liabilities, net of acquisitions
Accounts receivable
13,180
9,985
Inventory
(3,511
)
(3,142
)
Prepaid expenses and other assets
(1,060
)
84
Other non-current assets
(320
)
(365
)
Operating lease liabilities
(1,683
)
(1,553
)
Accounts payable
9,335
9,437
Accrued liabilities
(372
)
(5,309
)
Other, net
278
57
Net cash provided by (used in) operating activities
2,542
1,148
Cash flows from investing activities
Purchases of available-for-sale marketable securities
(18,669
)
(30,249
)
Sales and maturities of available-for-sale marketable securities
23,184
33,408
Purchases of property and equipment
(5,263
)
(8,310
)
Net cash provided by (used in) investing activities
(748
)
(5,151
)
Cash flows from financing activities
Proceeds from insurance premium financing
983
983
Debt issuance costs
(6
)
—
Payments on insurance premium financing
(735
)
(98
)
Proceeds from exercise of employee stock options
99
235
Taxes from withheld shares
(233
)
(415
)
Net cash provided by (used in) financing activities
108
705
Net increase (decrease) in cash and cash equivalents
1,902
(3,298
)
Cash and cash equivalents at beginning of period
10,708
11,350
Cash and cash equivalents at end of period
$
12,610
$
8,052
Supplemental disclosure of cash flow information
Cash paid for interest
$
2,193
$
2,495
Noncash investing activities
Unrealized (gains) losses, net on marketable securities
$
124
$
47
Noncash financing activities
Legal cost financing
$
1,176
$
228
Page | 7
Treace Medical Concepts, Inc.
Reconciliation of GAAP Net Loss to EBITDA & Adjusted EBITDA
(in thousands)
(unaudited)
Three Months EndedJune 30,
Six Months EndedJune 30,
2026
2025
2026
2025
Net loss
$
(15,873
)
$
(17,398
)
$
(33,834
)
$
(33,320
)
Adjustments:
Interest income
(445
)
(775
)
(946
)
(1,616
)
Interest expense
1,562
1,321
3,132
2,632
Taxes
—
—
—
—
Depreciation & Amortization
1,888
2,576
2,787
5,037
EBITDA
$
(12,868
)
$
(14,276
)
$
(28,861
)
$
(27,267
)
Share-based compensation expense
6,463
9,577
14,497
18,270
Restructuring costs1
805
—
1,009
—
Litigation costs2
2,052
1,055
4,322
1,510
Adjusted EBITDA
$
(3,548
)
$
(3,644
)
$
(9,033
)
$
(7,487
)
1 Restructuring charges primarily related to severance payments and other post-employment benefits.
2 Litigation costs related to intellectual property lawsuits.
Page | 8